Latest Alzinova News & Updates

See the latest news and media coverage for Alzinova. We track all announcements, press releases, and industry mentions in real time, all in one place.

Alzinova

Clinical-stage biopharmaceutical company developing Alzheimer’s disease vaccines

alzinova.com

Headquarters: Gothenburg, Sweden
Founded year: 2011
Company type: Public company
Number of employees: 9–10
Industry: Pharmaceuticals

Last updated October 7

Latest news about Alzinova

In short: Alzinova finalized seven US sites for Phase 2a ALZ-101 trial and raised SEK 44 million.

Company announcements

October 7 Alzinova

Alzinova raises SEK 44 million from fully subscribed rights issue

The rights issue reached 86.2 percent subscription without utilizing underwriting commitments.

October 6 Alzinova

Alzinova announces preliminary outcome of rights issue

The company raised 80.4 percent with SEK 41 million proceeds, triggering no underwriting commitment.

October 1 Alzinova

Alzinova closes rights issue today

SEK 51M funds Phase II ALZ-101 study and diagnostics development. Subscription period ends October 6, 2026.

September 21 Alzinova

Alzinova launches rights issue for Phase II study

The SEK 51 million funding supports the start-up of ALZ-101 vaccine trials, with enrollment targeted for late 2026. Subscription runs until October 6.

Media coverage

September 11 AffärsVärlden

Alzinova sees new equity issue for 51 million kronor

The biotech company Alzinova is conducting a rights issue to finance phase two studies. The share falls over 47 percent in exchange trading.

December 18, 2025 Placera

The board of Alzinova decides on a rights issue of units of approximately 50 MSEK | Placera.se

The board of Alzinova decides on a rights issue of units of approximately 50 MSEK...

September 8, 2025 GEN

Alzheimer's Vaccine Candidate ALZ-101 Begins Phase II Clinical Study

There are multiple different types of drugs available for the treatment of Alzheimer's disease: cholinesterase inhibitors to treat symptoms from mild to severe, and disease-modifying...

February 12, 2018 Dagens industri

Alzinova proposes two issuances ahead of Alzheimer's program

Alzinova ALZ -43.74%Today's development has in the rights issue received subscription commitments of approximately 3.8 million kronor and issue guarantees of approximately 26.3 million kronor, corresponding to a total of 100 percent...

Never miss news about Alzinova

Track Alzinova and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Alzinova competitors & trending companies

Browse news for competitors to Alzinova and other trending companies.